EICHOR
● Not Yet Recruiting
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Condition: Resectable Pancreatic Ductal Adenocarcinoma · Borderline Resectable Pancreatic Ductal Adenocarcinoma · Locally Advanced Pancreatic Ductal Adenocarcinoma · Sponsor: University of Washington
About this study
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Rachael Safyan, MD · 206-606-2038 · rsafyan@uw.edu
Isabel Blanco · 206-606-5864 · giresearch@fredhutch.org
Always discuss trial participation with your own doctor first.
Locations (1)
| Fred Hutch/University of Washington Cancer Consortium | Seattle, Washington, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.